Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry

Next Previous
X
Search
Trial Profile

A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM 101 (Primary) ; Capecitabine; Cetuximab; Cyclophosphamide; Fluorouracil; Folinic acid; Gemcitabine; Ipilimumab; Irinotecan; Nivolumab; Oxaliplatin; Paclitaxel; Pembrolizumab
  • Indications Advanced breast cancer; Cancer; Cholangiocarcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Pancreatic cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms MODULATE
  • Sponsors Immodulon Therapeutics

    • Most Recent Events

    • 10 Jul 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
    • 01 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top